Publications by authors named "S D Nimer"

Article Synopsis
  • The WHO and International Consensus Classification 2022 aim to improve diagnosis and treatment decisions for myelodysplastic syndromes, but disparities in their implementation exist.
  • A panel of experts used a data-driven method and the Delphi consensus process to align the two classifications, focusing on genomic features to create harmonized labels for distinct clusters.
  • Key findings identified nine genomic clusters, with the most significant linked to biallelic TP53 inactivation, and highlighted the inadequacy of traditional morphological assessments in capturing the complexity of these diseases.
View Article and Find Full Text PDF
Article Synopsis
  • Myelodysplastic neoplasms/syndromes (MDS) are a diverse set of diseases marked by ineffective blood cell production.
  • Recent classification systems by the World Health Organization and the International Consensus have provided more detailed categorizations of MDS based on morphology and genetics.
  • A comprehensive and systematic approach is essential for the accurate diagnosis and classification of MDS, as outlined by the International Consortium for MDS (icMDS).
View Article and Find Full Text PDF

SETD2 is the only enzyme responsible for transcription-coupled histone H3 lysine 36 trimethylation (H3K36me3). Mutations in SETD2 cause human diseases including cancer and developmental defects. In mice, Setd2 is essential for embryonic vascular remodeling.

View Article and Find Full Text PDF
Article Synopsis
  • SF3B1 mutations are common in cancer but lack directed treatments. Recent trials of XPO1 inhibitors in high-risk myelodysplastic neoplasms (MDS) found that patients with these mutations respond better to treatment.
  • The study explores how these mutations affect RNA behavior when XPO1 is inhibited, leading to altered splicing and activation of apoptotic pathways in the mutant cells.
  • Researchers identified that combining eltanexor (an XPO1 inhibitor) with venetoclax (a BCL2 inhibitor) effectively targets SF3B1 mutant cells while minimizing toxicity, paving the way for new treatment strategies for high-risk MDS.
View Article and Find Full Text PDF

SARS-CoV-2 is a virus that affects the human immune system. It was observed to be on the rise since the beginning of 2020 and turned into a life-threatening pandemic. Scientists have tried to develop a possible preventive and therapeutic drug against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and other related coronaviruses by assessing COVID-19-recovered persons' immunity.

View Article and Find Full Text PDF